RetinalVascularOcclusion near Brooklyn, NY

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience We are devoted to providing services that are patient centered and compassionate and care for you as a person nbsp;

Biography: Brian Marr, MD heads the Ophthalmic Oncology Service at the Harkness Eye Institute. He has comprehensive experience in the diagnosis, treatment, and management of ocular tumors including intraocular tumor resection, laser, radiation, and chemotherapy procedures. He has helped devise thousands of complex treatments for tumors of the eye, eyelid, orbit, and conjunctiva for his adult, children, and infant patients. Currently, Dr. Marr is a collaborator on a Columbia University clinical trial for a first-of-its-kind, new class of drug treatment for uveal melanoma. Dr. Marr is a board-certified ophthalmologist whose work has centered around ophthalmic oncology since 2000. One of the very few ocular oncologists trained in all aspects of eye cancer, Dr. Marr's clinical experience in treating these diseases is among the most extensive in the United States. His interest and experience in ophthalmic oncology began during an eight-year tenure in the Ocular Oncology Service at the Wills Eye Hospital in Philadelphia. There, he gained extensive experience treating intraocular tumors, and tumors of the eyelid, orbit, and conjunctiva in children and adults. It was there that Dr. Marr developed and improved many surgical procedures used to cure cancers of the eye, successfully treated thousands of patients, and helped their families though their battle with eye cancer. Next, Dr. Marr moved on to Memorial Sloan Kettering Cancer Center, where he remain for nine years, starting in 2008. Dr. Marr has some of the greatest experience with intra-arterial chemotherapy for treating retinoblastoma in the country, if not the world, as well as all other forms of retinoblastoma treatment. He has been a key member of many multidisciplinary surgical teams, treating advanced skull base tumors and complex facial skin lesions. He has developed a strong belief and treatment philosophy that the best research be used to help his patients, rather than his best patients be used to help his research. The field of ophthalmic oncology encompasses many rare conditions and his experience helps his patients get the best care and results as quickly as possible. Dr. Marr lectures and consults across the US and abroad, and has authored numerous research articles in the field of ocular oncology. He is the principal investigator in a first-in-class drug study for treating primary uveal melanoma, in an international, multi-center trial. He also volunteers his medical expertise in underserviced parts of the world, such as Nigeria and Indonesia, and has helped train physicians in more than 20 countries. Dr. Marr's efforts as a contributor to ongoing education in ocular oncology have been recognized by the American Academy of Ophthalmology, where he now serves as chief editor of the Academy's Oncology and Pathology's One network.

Care Philosophy: At University of Louisville Physicians we are committed to the delivering the very finest health care to our patients and their families and serving them with personalized care and compassion As professors and researchers at the UofL School of Medici

Biography: Dr. Jeffrey M. Liebmann is a Professor of Ophthalmology, Glaucoma Service Director, and Vice-Chair for the Department of Ophthalmology at Columbia University Medical Center. Dr. Jeffrey M. Liebmann graduated from Boston University School of Medicine, completed his ophthalmology residency at the State University of New York/Downstate Medical Center, and his glaucoma fellowship at the New York Eye and Ear Infirmary. Dr. Liebmann serves as Shirlee and Bernard Brown Professor, Vice-Chair, and Director of the Glaucoma Division of the Department Ophthalmology at Columbia University Medical Center. He is a fellow of the American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology and American College of Surgeons. Dr. Liebmann is currently Editor-in-Chief of Journal of Glaucoma, a member of the Board of Governors of the World Glaucoma Association and Board of Directors of The Glaucoma Foundation and Secretary-Treasurer of the New York Glaucoma Society. Dr. Liebmann is a past-President of the World Glaucoma Association, American Glaucoma Society, and the New York Society for Clinical Ophthalmology and was co-founder of the New York Glaucoma Research Institute, the American Glaucoma Society Foundation and ASCRS Glaucoma Day. In addition to maintaining a busy tertiary-care referral practice in New York City, Dr. Liebmann is Principal Investigator for the NIH African Descent and Glaucoma Evaluation Study (ADAGES) and Ocular Hypertension Treatment Study (OHTS III) at Columbia University and is the author and/or co-author of more than 1000 medical and scientific papers, book chapters, and abstracts. He has lectured widely in the United States and abroad on glaucoma diagnosis and management. His current main areas of research interest include the causes of glaucoma, glaucoma progression, glaucoma surgery, ocular imaging, and neuroprotection.

Biography: Dr. Rafla-Demetrious is an Assistant Professor of Ophthalmology at the Weill Cornell Medicine. She received a B.A. from the University of Pennsylvania and received her M.D. from SUNY Downstate, graduating with the distinct honor of Summa Cum Laude.Dr. Rafla-Demetrious did her medical internship at St. Vincent's Medical Center in N.Y.C, New York. Thereafter, she began her Ophthalmology residency at New York Presbyterian Hospital, Weill Medical College of Cornell University in New York City in 1994. She then remained there to continue her Fellowship in Glaucoma. Upon completion, she joined the Department of Ophthalmology at New York Presbyterian Hospital, Weill Medical College as an Assistant Professor of Ophthalmology in 2000.Dr. Rafla-Demetrious's clinical practice specializes in the diagnosis and treatment of glaucoma and anterior segment diseases.Dr. Rafla Demetrious received honors from the Alpha Omega Alpha (AA) in 1991.